Cangemi V, Volpino P, D'Andrea N, Galati G, Ramacciato G, Puopolo M, Cangemi R, Piat G
1st Department of Surgery, University of Rome La Sapienza, Italy.
Panminerva Med. 1996 Mar;38(1):1-7.
Despite the increasing frequency of lung cancer, the percentage occurring in young patients is very low (1.3-5.5% of all lung cancers). In 1992, of the 78,124 cases observed in Italy, 2.8% involved patients under 40 years of age. We reviewed a series of 800 patients with histologically proven lung cancer, candidates to a long-term follow-up. Of these, 23 (2.9%) were under 40 years of age, with a low male/female ratio (1.87:1). Fifty-two percent were smokers and 82.6% presented symptoms as the time of diagnosis. The most frequent histologic types were adenocarcinoma and large-cell type, which carried a better outcome (10-year survival of 28.5%) than epidermoid and small-cell types (p = 0.013). These tumors detected in 13% and 17.4% of cases, were unresectable (except for one epidermoid carcinoma), with a survival expectancy of 0% at two years. Considering all patients, resection was possible in nine cases, being curative in seven, with an overall 10-year survival rate of 44.4% (p = 0.002 vs non-resected patients). Stage I-II had the best prognosis with a 10-year survival rate of 80% (p = 0.022 vs resected stage III-IV). Patients undergoing primary chemotherapy and/or radiotherapy had the worst prognosis with no survivors at 30 months. In young patients clinical and pathological parameters had almost the same distribution except for sex and histologic type and offered almost the same survival probability as in patients over 40 years of age. When prognostic findings were tested by univariate analysis, only resectability was found to have an independent favourable impact on survival (hazard risk: 7.47; 95% confidence interval: 1.50-37.14).
尽管肺癌的发病率不断上升,但年轻患者中肺癌的比例非常低(占所有肺癌的1.3 - 5.5%)。1992年,在意大利观察到的78124例病例中,2.8%的患者年龄在40岁以下。我们回顾了一系列800例经组织学证实为肺癌且需长期随访的患者。其中,23例(2.9%)年龄在40岁以下,男女比例较低(1.87:1)。52%为吸烟者,82.6%在诊断时出现症状。最常见的组织学类型是腺癌和大细胞型,其预后(10年生存率为28.5%)优于表皮样癌和小细胞型(p = 0.013)。这些肿瘤在13%和17.4%的病例中无法切除(除1例表皮样癌外),两年生存率为0%。考虑所有患者,9例可行切除术,7例治愈,总体10年生存率为44.4%(与未切除患者相比,p = 0.002)。I - II期预后最佳,10年生存率为80%(与切除的III - IV期相比,p = 0.022)。接受一线化疗和/或放疗的患者预后最差,30个月时无幸存者。在年轻患者中,除性别和组织学类型外,临床和病理参数的分布几乎相同,其生存概率与40岁以上患者几乎相同。当通过单因素分析检验预后结果时,仅发现可切除性对生存有独立的有利影响(风险比:7.47;95%置信区间:1.50 - 37.14)。